Welcome to our dedicated page for NovaBridge Biosciences SEC filings (Ticker: NBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NovaBridge Biosciences (NBP) SEC filings page on Stock Titan provides access to the company’s official disclosures as a foreign private issuer listed on Nasdaq. NovaBridge, formerly known as I-Mab, files reports such as Form 20-F and Form 6-K that describe its financial condition, risk factors, and operational progress as a global biotechnology platform company.
In these filings, NovaBridge outlines its business model, which combines business development and translational clinical development to advance a pipeline led by givastomig, ragistomig, uliledlimab, and VIS-101. Management’s discussion and analysis sections describe how the company allocates resources to oncology and ophthalmology programs, summarizes its collaborations with partners such as ABL Bio, and explains the structure of subsidiaries like Visara within its hub-and-spoke framework.
Investors reviewing NovaBridge’s SEC reports can examine clinical development disclosures for givastomig, including its positioning as a Claudin 18.2 x 4-1BB bispecific antibody in gastric and other gastrointestinal cancers, and for ragistomig as a PD-L1 x 4-1BB bispecific in solid tumors. Filings also discuss rights to uliledlimab outside Greater China and the VIS-101 license and assignment arrangements involving Visara and Everest Medicines.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as segment descriptions, collaboration agreements, share incentive plans, and subsequent events. Users can follow new 6-K submissions for interim updates, and consult annual filings for a more comprehensive view of NovaBridge’s strategy, risk profile, and pipeline.
By using this page, investors and researchers can monitor NovaBridge’s official SEC communications in real time, while AI-generated insights help interpret complex biotech and capital markets information contained in the original documents.
NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew reported a combination of option activity and share sales. He sold 8,494 Ordinary Shares in an open-market sale at $0.66 per share and, the prior day, exercised derivative awards into 10,302 Ordinary Shares represented by American Depositary Shares (ADSs). Following these transactions, he directly held 157,941 Ordinary Shares and 82,422 Restricted Share Units (RSUs), which each represent a right to receive one ADS.
NovaBridge Biosciences filed Amendment No. 1 to its Form 20-F to correct previously reported beneficial ownership information. The company states that these corrections do not affect its audited financial statements. Updated data show 265,377,891 ordinary shares outstanding as of December 31, 2025 and 265,991,561 shares outstanding as of March 24, 2026.
The amendment refreshes ownership details for directors, executives and major holders, including stakes held through American depositary shares and affiliated investment entities, while confirming the company is not aware of any arrangement that may result in a change of control.
NovaBridge Biosciences changed its independent auditor after the Audit Committee dismissed PricewaterhouseCoopers LLP and appointed Deloitte Touche Tohmatsu Certified Public Accountants LLP, both actions effective June 16, 2026. PwC’s audit reports for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.
The filing notes there were no disagreements with PwC on accounting, disclosure, or audit procedures, and no reportable events other than previously disclosed material weaknesses in information technology general controls as of December 31, 2025 and 2024. NovaBridge also states it did not consult Deloitte on accounting or audit issues before the appointment. This 6-K is incorporated by reference into the company’s existing Form F-3 and multiple Form S-8 registration statements.
NovaBridge Biosciences reports that the FDA has granted Fast Track Designation to its bispecific antibody givastomig in combination with nivolumab and chemotherapy for previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinoma with CLDN18.2- and PD-L1-positive tumors. Early Phase 1b data showed strong efficacy and tolerability, supporting further development. NovaBridge plans to start a registrational Phase 3 trial as early as Q4 2026 and expects to present detailed Phase 1b results at a major medical conference in H2 2026. The company also highlights a broader pipeline, including retinal drug VIS-101 and additional immuno-oncology candidates developed through partnerships.
NovaBridge Biosciences SVP, Clinical Development Xu Cong Claire reported a mix of derivative exercises and a small open‑market sale of company stock. On June 1, 2026, she sold 3,494 Ordinary Shares at an average price of $3.94 per share in an open‑market transaction. On May 30, 2026, she exercised derivative awards to acquire additional Ordinary Shares, including Restricted Share Units (RSUs) covering 4,079 Ordinary Shares. After these transactions, she directly owns 290,154 Ordinary Shares and 32,637 RSUs. Footnotes state that Ordinary Shares are represented by American Depositary Shares (ADSs), where each 10 ADSs represent 23 Ordinary Shares, and her reported holdings correspond to 126,154 ADSs.
NovaBridge Biosciences director and officer Cao Sean Wuxiong reported an open-market sale of ADSs tied to equity compensation. He sold 9,304 American Depositary Shares (ADSs), representing approximately 21,399 ordinary shares, at a price expressed in ADS terms of $1.99. According to the footnotes, this sale was made in connection with the partial vesting of a restricted stock unit award on January 31, 2026, solely to cover tax withholding obligations related to that vesting. Following the transaction, he holds 35,073 ordinary shares, represented by 15,249 ADSs, indicating this was a routine tax-related disposition rather than a full exit.
NovaBridge Biosciences officer Mark Arnold Hagler reported an open-market purchase of 230,000 Ordinary Shares, represented by 100,000 American Depositary Shares (ADSs). The weighted average purchase price was $2.51 per ADS, with individual trades between $2.44 and $2.54. Following the transaction, he directly holds 230,000 Ordinary Shares.
NovaBridge Biosciences filed an initial Form 3 for Hagler Mark Arnold, who is identified as an officer of the company with the title noted as “See Remarks.” The filing does not report any transactions or holdings, serving as an initial beneficial ownership statement.
NovaBridge Biosciences appointed Mark Hagler as President and Chief Commercial Officer, effective April 17, 2026, adding senior commercial leadership as its oncology and ophthalmology pipeline advances. Hagler has more than 25 years of biopharma experience, including leading a $1 billion-plus portfolio and over 600 staff at Sun Pharmaceutical Industries.
He previously held senior roles at Ipsen, Sanofi, Novartis and Abraxis BioScience, helping launch key oncology drugs such as Abraxane and Afinitor. His commercial and pre-commercial expertise is expected to support NovaBridge’s mid-stage programs, including the Claudin 18.2 x 4-1BB bispecific antibody givastomig and the dual VEGF-A x ANG-2 inhibitor VIS-101, as they move toward pivotal and Phase 2b studies.